Back to Search
RONALD BUKOWSKI, MD
MD
Hematology & Oncology Physician
NPI: 1952365603Individual
Specialties, Licenses & Credentials
Hematology & Oncology PhysicianPrimary
Internal Medicine — Hematology & Oncology
Code: 207RH0003X
35030732B(OH)
Research & Publications (20)
Targeted Therapies: Bevacizumab and interferon-alpha in metastatic renal-cell carcinoma.
PMID 19390549·Nat Rev Clin Oncol·2009
8-other
Prognostic factors for survival in metastatic renal cell carcinoma: update 2008.
PMID 19402065·Cancer·2009
6-review
An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial.
PMID 18602688·Lancet·2008
3-trial
Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer.
PMID 17876014·J Clin Oncol·2007
3-trial
Effects of sorafenib on symptoms and quality of life: results from a large randomized placebo-controlled study in renal cancer.
PMID 17551296·Am J Clin Oncol·2007
3-trial
Targeted therapy for cytokine-refractory metastatic renal cell carcinoma, and treatment in the community.
PMID 16773842·Oncology (Williston Park)·2006
5-case
New antiangiogenic agents for renal cell carcinoma: interferon alfa and thalidomide.
PMID 14751084·Curr Oncol Rep·2004
8-other
Prognostic factors in patients with advanced renal cell carcinoma: development of an international kidney cancer working group.
PMID 15448023·Clin Cancer Res·2004
8-other
New antiangiogenic agents for renal cell carcinoma: bevacizumab.
PMID 14751083·Curr Oncol Rep·2004
8-other
AE-941, a multifunctional antiangiogenic compound: trials in renal cell carcinoma.
PMID 12882625·Expert Opin Investig Drugs·2003
6-review
Treating cancer with PEG Intron: pharmacokinetic profile and dosing guidelines for an improved interferon-alpha-2b formulation.
PMID 12124839·Cancer·2002
6-review
Pegylated interferon alfa-2b treatment for patients with solid tumors: a phase I/II study.
PMID 12228203·J Clin Oncol·2002
3-trial
Development of novel signal transduction inhibitors; recent phase I trials.
PMID 11734108·Curr Oncol Rep·2002
8-other
Cytokine combinations: therapeutic use in patients with advanced renal cell carcinoma.
PMID 10768599·Semin Oncol·2000
6-review
Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial.
PMID 19615940·Lancet Oncol·2009
3-trial
Inhibition of proteasome activity by bortezomib in renal cancer cells is p53 dependent and VHL independent.
PMID 19661301·Anticancer Res·2009
8-other
T-REX: software for the processing and analysis of T-RFLP data.
PMID 19500385·BMC Bioinformatics·2009
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 9500 EUCLID AVE
CLEVELAND, OH 44195 - Phone
- (800) 223-2273
Quick Facts
- NPI
- 1952365603
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile